ATOS · Atossa Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Steven C. Quay President & CEO | ▲ Buy | Grant | 88,038 Shares held | 3/27/2026 | View profile |
| Mark James Daniel Chief Financial Officer | ▲ Buy | Grant | 63,000 Shares held | 3/26/2026 | View profile |
| Jonathan Finn 10% Owner | ▲ Buy | Grant | 11,666 Shares held | 5/12/2026 | View profile |
| H. Lawrence Remmel | ▲ Buy | Grant | 10,683 Shares held | 5/12/2026 | View profile |
| Stephen J. Galli | ▲ Buy | Grant | 10,006 Shares held | 5/12/2026 | View profile |
| Shu-Chih Chen | ▲ Buy | Grant | 10,000 Shares held | 5/12/2026 | View profile |
| Tessa Cigler | ▲ Buy | Grant | 10,000 Shares held | 5/12/2026 | View profile |
| Richard I. Steinhart Director | ▲ Buy | Grant | 10,000 Shares held | 5/12/2026 | View profile |
| Gregory L. Weaver Chief Financial Officer | ▼ Sell | Open Market | 55 Shares held | 11/15/2023 | View profile |
Transaction History
| Richard I. Steinhart | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 |
| Shu-Chih Chen | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 |
| H. Lawrence Remmel | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 |
| Jonathan Finn | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 |
| Stephen J. Galli | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 |
| Tessa Cigler | ▲ Buy | Grant | 10,000 | $0 | 5/12/2026 |
| Steven C. Quay | ▲ Buy | Grant | 65,000 | $0 | 3/27/2026 |
| Mark James Daniel | ▲ Buy | Grant | 63,000 | $0 | 3/26/2026 |
| Steven C. Quay | ▲ Buy | Grant | 325,203 | $0 | 1/20/2026 |
| Steven C. Quay | ▲ Buy | Open Market | 11,239 | $10K | 5/21/2025 |
| H. Lawrence Remmel | ▲ Buy | Open Market | 10,000 | $7K | 3/26/2025 |
| Jonathan Finn | ▲ Buy | Open Market | 25,000 | $44K | 4/10/2024 |
| Gregory L. Weaver | ▼ Sell | Open Market | 50,000 | $33K | 11/15/2023 |
| Gregory L. Weaver | ▲ Buy | Open Market | 50,000 | $49K | 6/20/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Atossa Announces Stapled CVR Plan and Raises Price Target
Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.
Atossa Announces Stapled CVR Plan and Raises Price Target. Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.